CN112805031A - 阿尔茨海默病的治疗及预防方法 - Google Patents

阿尔茨海默病的治疗及预防方法 Download PDF

Info

Publication number
CN112805031A
CN112805031A CN201980062781.8A CN201980062781A CN112805031A CN 112805031 A CN112805031 A CN 112805031A CN 201980062781 A CN201980062781 A CN 201980062781A CN 112805031 A CN112805031 A CN 112805031A
Authority
CN
China
Prior art keywords
months
subject
administration
relative
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980062781.8A
Other languages
English (en)
Chinese (zh)
Inventor
J·鲁特曼
C·J·斯万森
Y·张
S·达达
J·王
L·克拉默
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanitary Material R&d Management Co ltd
Original Assignee
Sanitary Material R&d Management Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanitary Material R&d Management Co ltd filed Critical Sanitary Material R&d Management Co ltd
Priority to CN202411217698.2A priority Critical patent/CN118924896A/zh
Publication of CN112805031A publication Critical patent/CN112805031A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201980062781.8A 2018-07-24 2019-07-23 阿尔茨海默病的治疗及预防方法 Pending CN112805031A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202411217698.2A CN118924896A (zh) 2018-07-24 2019-07-23 阿尔茨海默病的治疗及预防方法

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201862702659P 2018-07-24 2018-07-24
US62/702,659 2018-07-24
US201862749614P 2018-10-23 2018-10-23
US62/749,614 2018-10-23
US201962824162P 2019-03-26 2019-03-26
US62/824,162 2019-03-26
US201962846902P 2019-05-13 2019-05-13
US62/846,902 2019-05-13
US201962874684P 2019-07-16 2019-07-16
US62/874,684 2019-07-16
PCT/US2019/043067 WO2020023530A2 (en) 2018-07-24 2019-07-23 Methods of treatment and prevention of alzheimer's disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202411217698.2A Division CN118924896A (zh) 2018-07-24 2019-07-23 阿尔茨海默病的治疗及预防方法

Publications (1)

Publication Number Publication Date
CN112805031A true CN112805031A (zh) 2021-05-14

Family

ID=67551415

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201980062781.8A Pending CN112805031A (zh) 2018-07-24 2019-07-23 阿尔茨海默病的治疗及预防方法
CN202411217698.2A Pending CN118924896A (zh) 2018-07-24 2019-07-23 阿尔茨海默病的治疗及预防方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202411217698.2A Pending CN118924896A (zh) 2018-07-24 2019-07-23 阿尔茨海默病的治疗及预防方法

Country Status (13)

Country Link
US (1) US20210324056A1 (enExample)
EP (1) EP3826674A2 (enExample)
JP (2) JP7541505B2 (enExample)
KR (1) KR20210039402A (enExample)
CN (2) CN112805031A (enExample)
AU (1) AU2019309938A1 (enExample)
BR (1) BR112021001272A2 (enExample)
CA (1) CA3107370A1 (enExample)
IL (3) IL280315B2 (enExample)
MX (1) MX2021000778A (enExample)
PH (1) PH12021500006A1 (enExample)
TW (1) TW202019471A (enExample)
WO (1) WO2020023530A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019023247A1 (en) 2017-07-25 2019-01-31 Immutics, Inc. TREATMENT OF CANCER BY BLOCKING THE INTERACTION OF TIM-3 AND ITS LIGAND
EP3918323A4 (en) 2019-01-30 2022-12-28 TrueBinding, Inc. ANTI-GAL3 ANTIBODIES AND USES THEREOF
HRP20251087T1 (hr) * 2020-03-20 2025-11-07 Eisai R&D Management Co., Ltd. Formulacije visoke koncentracije anti-amiloidnih beta peptidnih protofibrilnih protutijela i postupci njihove upotrebe
WO2021242776A2 (en) 2020-05-26 2021-12-02 Truebinding, Inc. Methods of treating inflammatory diseases by blocking galectin-3
MX2023000949A (es) 2020-07-23 2023-02-22 Othair Prothena Ltd Anticuerpos anti-beta-amiloide (abeta).
US20230302009A1 (en) * 2020-08-12 2023-09-28 The Cleveland Clinic Foundation Bace1 inhibitor treatment for suppressing cytokine storm
WO2023111618A1 (en) * 2021-12-17 2023-06-22 Eisai R&D Management Co., Ltd. Methods of using an anti-amyloid beta protofibril antibody and anti-tau antibody
AU2022410770A1 (en) * 2021-12-17 2024-06-13 Eisai R&D Management Co., Ltd. Methods of using an anti-amyloid beta protofibril antibody and anti-tau antibody
AU2022439338A1 (en) * 2022-02-02 2024-08-15 Eisai R&D Management Co., Ltd. Methods of treatment using p-tau181 level

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101421303A (zh) * 2006-03-23 2009-04-29 生命北极神经科学公司 改进的初原纤维选择性抗体及其用途
WO2017127764A1 (en) * 2016-01-20 2017-07-27 Genentech, Inc. High dose treatments for alzheimer's disease
WO2018005282A1 (en) * 2016-07-01 2018-01-04 Eli Lilly And Company ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF
WO2018081460A1 (en) * 2016-10-27 2018-05-03 Eisai R&D Management Co., Ltd. Composition comprising an anti-abeta protofibril antibody and a beta-secretase bace1 inhibitor for the treatment of alzheimer's disease

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1309341A2 (en) 2000-07-07 2003-05-14 Lars Lannfelt Prevention and treatment of alzheimer's disease
SE0401601D0 (sv) 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
JO3076B1 (ar) * 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
AU2016208353B2 (en) * 2007-10-17 2017-07-20 Janssen Alzheimer Immunotherapy Immunotherapy regimes dependent on ApoE status
US20100317850A1 (en) 2008-01-18 2010-12-16 Yuichi Suzuki Condensed aminodihydrothiazine derivative
PL2448968T3 (pl) 2009-06-29 2021-09-13 Bioarctic Ab Antybiotyki selektywne względem n-końcowych skróconych protofibryli/oligomerów amyloidu beta
JP2013521233A (ja) * 2010-02-25 2013-06-10 ヤンセン アルツハイマー イミュノセラピー Ａβを標的とする免疫療法のＰＥＴモニタリング
CN102869680B (zh) 2010-02-26 2016-10-05 生命北极神经科学公司 原细纤维结合抗体及其在帕金森氏症、路易体痴呆和其他α-共核蛋白病的治疗和诊断方法中的应用
SG191710A1 (en) 2011-01-21 2013-08-30 Eisai R&D Man Co Ltd Methods and compounds useful in the synthesis of fused aminodihydrothiazine derivatives
PE20170768A1 (es) 2014-07-10 2017-07-04 Eisai Randd Man Co Ltd Anticuerpos de union a protofibrillas ab mejorados
MA41115A (fr) * 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
EP3454904B1 (en) * 2016-05-13 2022-12-14 Institut Pasteur Inhibition of beta-2 nicotinic acetylcholine receptors to treat alzheimer's disease pathology

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101421303A (zh) * 2006-03-23 2009-04-29 生命北极神经科学公司 改进的初原纤维选择性抗体及其用途
WO2017127764A1 (en) * 2016-01-20 2017-07-27 Genentech, Inc. High dose treatments for alzheimer's disease
WO2018005282A1 (en) * 2016-07-01 2018-01-04 Eli Lilly And Company ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF
TW201811363A (zh) * 2016-07-01 2018-04-01 美商美國禮來大藥廠 抗－N3pGlu類澱粉β肽抗體及其用途
WO2018081460A1 (en) * 2016-10-27 2018-05-03 Eisai R&D Management Co., Ltd. Composition comprising an anti-abeta protofibril antibody and a beta-secretase bace1 inhibitor for the treatment of alzheimer's disease

Also Published As

Publication number Publication date
IL280315B1 (en) 2024-02-01
BR112021001272A2 (pt) 2021-04-27
CN118924896A (zh) 2024-11-12
EP3826674A2 (en) 2021-06-02
IL310132B1 (en) 2025-11-01
MX2021000778A (es) 2021-03-31
IL323583A (en) 2025-11-01
IL280315B2 (en) 2024-06-01
IL310132A (en) 2024-03-01
JP7541505B2 (ja) 2024-08-28
JP2024112859A (ja) 2024-08-21
JP2021532126A (ja) 2021-11-25
CA3107370A1 (en) 2020-01-30
WO2020023530A2 (en) 2020-01-30
KR20210039402A (ko) 2021-04-09
PH12021500006A1 (en) 2021-09-13
WO2020023530A3 (en) 2020-03-12
IL280315A (en) 2021-03-25
AU2019309938A1 (en) 2021-03-11
US20210324056A1 (en) 2021-10-21
TW202019471A (zh) 2020-06-01

Similar Documents

Publication Publication Date Title
CN112805031A (zh) 阿尔茨海默病的治疗及预防方法
EP3003356B1 (en) Il-1 antagonists for use in treating alzheimer's disease
US20250163135A1 (en) Biomarkers for alzheimer's disease treatment
US20200330592A1 (en) Compositions and methods of treating alzheimer's and other amyloid related diseases
KR20190102181A (ko) 알츠하이머병의 치료를 위한 항-a베타 원시섬유 항체 및 베타-세크레타제 bace1 억제제를 포함하는 조성물
KR20240142535A (ko) P-tau181 수준을 사용한 치료 방법
TW202328178A (zh) 抗Ａβ初原纖維抗體的皮下配製物及其使用方法
EP4626918A1 (en) Methods of treatment using a tau pet level
CN117940773A (zh) 用于阿尔茨海默病治疗的生物标记物
RU2832167C2 (ru) Способы лечения и предупреждения болезни альцгеймера
BR122025003268A2 (pt) Métodos de tratamento e prevenção de doença de alzheimer
CN118786141A (zh) 使用p-tau181水平的治疗方法
TW202518027A (zh) 抗微生物肽
Hyttinen Long-term effects of the cholesterol level and its drug treatment
HK1220896B (en) Il-1 antagonists for use in treating alzheimer's disease

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination